Literature DB >> 22129991

Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases.

Daniel W Neef1, Alex M Jaeger, Dennis J Thiele.   

Abstract

Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and prion-based neurodegeneration are associated with the accumulation of misfolded proteins, resulting in neuronal dysfunction and cell death. However, current treatments for these diseases predominantly address disease symptoms, rather than the underlying protein misfolding and cell death, and are not able to halt or reverse the degenerative process. Studies in cell culture, fruitfly, worm and mouse models of protein misfolding-based neurodegenerative diseases indicate that enhancing the protein-folding capacity of cells, via elevated expression of chaperone proteins, has therapeutic potential. Here, we review advances in strategies to harness the power of the natural cellular protein-folding machinery through pharmacological activation of heat shock transcription factor 1--the master activator of chaperone protein gene expression--to treat neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129991      PMCID: PMC3518299          DOI: 10.1038/nrd3453

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  183 in total

Review 1.  Huntington's disease.

Authors:  Francis O Walker
Journal:  Lancet       Date:  2007-01-20       Impact factor: 79.321

2.  A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity.

Authors:  Sabah Ansar; Joseph A Burlison; M Kyle Hadden; Xiao Ming Yu; Kelly E Desino; Jennifer Bean; Len Neckers; Ken L Audus; Mary L Michaelis; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2007-01-17       Impact factor: 2.823

3.  Heat shock factor 2 (HSF2) contributes to inducible expression of hsp genes through interplay with HSF1.

Authors:  Päivi Ostling; Johanna K Björk; Pia Roos-Mattjus; Valérie Mezger; Lea Sistonen
Journal:  J Biol Chem       Date:  2007-01-09       Impact factor: 5.157

4.  A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.

Authors:  Grzegorz S Nowakowski; Andrea K McCollum; Matthew M Ames; Sumithra J Mandrekar; Joel M Reid; Alex A Adjei; David O Toft; Stephanie L Safgren; Charles Erlichman
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 5.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.

Authors:  Christian Haass; Dennis J Selkoe
Journal:  Nat Rev Mol Cell Biol       Date:  2007-02       Impact factor: 94.444

6.  The induction mechanism of the molecular chaperone HSP70 in the gastric mucosa by Geranylgeranylacetone (HSP-inducer).

Authors:  Michiro Otaka; Soh Yamamoto; Kaori Ogasawara; Yuka Takaoka; Susumu Noguchi; Toshio Miyazaki; Akira Nakai; Masaru Odashima; Tamotsu Matsuhashi; Sumio Watanabe; Hideaki Itoh
Journal:  Biochem Biophys Res Commun       Date:  2006-12-13       Impact factor: 3.575

Review 7.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Nat Rev Neurosci       Date:  2010-11-19       Impact factor: 34.870

8.  Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio).

Authors:  Sifeng Wang; Kechun Liu; Ximing Wang; Qiuxia He; Xiqiang Chen
Journal:  Drug Chem Toxicol       Date:  2010-10-18       Impact factor: 3.356

9.  Protein kinase A binds and activates heat shock factor 1.

Authors:  Ayesha Murshid; Shiuh-Dih Chou; Thomas Prince; Yue Zhang; Ajit Bharti; Stuart K Calderwood
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

10.  SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.

Authors:  Dohoon Kim; Minh Dang Nguyen; Matthew M Dobbin; Andre Fischer; Farahnaz Sananbenesi; Joseph T Rodgers; Ivana Delalle; Joseph A Baur; Guangchao Sui; Sean M Armour; Pere Puigserver; David A Sinclair; Li-Huei Tsai
Journal:  EMBO J       Date:  2007-06-21       Impact factor: 11.598

View more
  130 in total

1.  Protein conformational diseases: Rescuing protein homeostasis.

Authors:  Sarah Crunkhorn
Journal:  Nat Rev Drug Discov       Date:  2012-01-20       Impact factor: 84.694

Review 2.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

3.  Multifactorial Attenuation of the Murine Heat Shock Response With Age.

Authors:  Donald A Jurivich; Gunjan D Manocha; Rachana Trivedi; Mary Lizakowski; Sharlene Rakoczy; Holly Brown-Borg
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-09-25       Impact factor: 6.053

4.  Pre-exposure to fine particulate matters may induce endotoxin tolerance in a mouse model.

Authors:  Yuntao Bai; Bo Lu; Qinghua Sun
Journal:  Austin J Environ Toxicol       Date:  2015-05-05

5.  Mammalian Heat Shock Response and Mechanisms Underlying Its Genome-wide Transcriptional Regulation.

Authors:  Dig B Mahat; H Hans Salamanca; Fabiana M Duarte; Charles G Danko; John T Lis
Journal:  Mol Cell       Date:  2016-03-24       Impact factor: 17.970

6.  Purification, crystallization and X-ray diffraction analysis of the DNA-binding domain of human heat-shock factor 2.

Authors:  Han Feng; Wei Liu; Da Cheng Wang
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-03-16       Impact factor: 1.056

Review 7.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 8.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 9.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

10.  Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail.

Authors:  Suman Ghosh; Yang Liu; Gaurav Garg; Mercy Anyika; Nolan T McPherson; Jiacheng Ma; Rick T Dobrowsky; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2016-07-05       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.